Convalescent plasma therapy of a new coronavirus infection: an experience of Moscow city hospitals

Bulanov A.Y.

N.V. Sklifosovsky Research Institute of Emergency Medicine

ORCID: 0000-0001-6999-8145

Kostin A.I.

Sklifosovsky Research Institute for Emergency Care

Petrikov S.S.

Sklifosovsky Clinical and Research Institute for Emergency Care

ORCID: 0000-0003-3292-8789

Lysenko M.A.

Moscow City Hospital No. 52;
Pirogov Russian National Research Medical University

Popugaev K.A.

Sklifosovsky Research Institute for Emergency Care

ORCID: 0000-0002-6240-820X

Fomina D.S.

Sechenov First Moscow State Medical University (Sechenov University);
City Clinical Hospital No. 52

ORCID: 0000-0002-5083-6637

Ladygina E.A.

Sklifosovsky Research Institute for Emergency Care

Simarova I.B.

Moscow City Hospital No. 52;
Sklifosovsky Research Institute for Emergency Care

Filatova A.P.

Sklifosovsky Research Institute for Emergency Care

Mutovina Z.Yu.

Moscow City Hospital No. 52;
Central State Medical Academy

Kovalevskaya E.A.

Moscow City Hospital No. 52

Unmut S.S.

Center of Analytical Development of Social Sector

Maltseva N.P.

Moscow City Hospital No. 52

Vasin E.A.

Moscow City Hospital No. 52

Convalescent plasma therapy of a new coronavirus infection: an experience of Moscow city hospitals

Authors:

Bulanov A.Y., Kostin A.I., Petrikov S.S., Lysenko M.A., Popugaev K.A., Fomina D.S., Ladygina E.A., Simarova I.B., Filatova A.P., Mutovina Z.Yu., Kovalevskaya E.A., Unmut S.S., Maltseva N.P., Vasin E.A.

More about the authors

Journal: Russian Journal of Anesthesiology and Reanimatology. 2020;(6‑2): 33‑39

DOI: 10.17116/anaesthesiology202006233

Downloaded: 111

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Bulanov AY, Kostin AI, Petrikov SS, et al. . Convalescent plasma therapy of a new coronavirus infection: an experience of Moscow city hospitals. Russian Journal of Anesthesiology and Reanimatology. 2020;(6‑2):33‑39. (In Russ.)
https://doi.org/10.17116/anaesthesiology202006233

Использование инфографики авторами научных работ

Close metadata

An actual current problem is therapy of a new coronavirus infection. An important feature of COVID-19 pandemic is the absence of standard therapy. All available remedies are experimental. Considering the experience of previous viral pandemics, we can assume the effect of convalescent plasma therapy of COVID-19 infection. In this manuscript, we have analyzed an experience of convalescent plasma therapy of COVID-19 infection plasma in the Moscow city hospitals.

OBJECTIVE

To analyze the first experience of convalescent plasma therapy of a new coronavirus infection in the Moscow city hospitals.

MATERIAL AND METHODS

Fresh frozen plasma (FFP) obtained by apheresis and subjected to pathogen reduction was transfused to 226 patients with moderate-to-severe COVID-19 infection. The control group retrospectively included 226 patients with similar characteristics.

RESULTS

We found significantly reduced mortality after 10 (5.3 vs 17.2%) and 28 days (14.2 vs 50%) in the main group. These differences were more significant for patients who did not require mechanical ventilation (relative risk of death 0.369, 95% CI 0.159-0.859).

CONCLUSION

Convalescent plasma therapy is effective for COVID-19 infection. In particular, this approach is advisable in patients with significant respiratory failure and no need for mechanical ventilation.

Keywords:

COVID-19

treatment

convalescent plasma

Authors:

Bulanov A.Y.

N.V. Sklifosovsky Research Institute of Emergency Medicine

ORCID: 0000-0001-6999-8145

Kostin A.I.

Sklifosovsky Research Institute for Emergency Care

Petrikov S.S.

Sklifosovsky Clinical and Research Institute for Emergency Care

ORCID: 0000-0003-3292-8789

Lysenko M.A.

Moscow City Hospital No. 52;
Pirogov Russian National Research Medical University

Popugaev K.A.

Sklifosovsky Research Institute for Emergency Care

ORCID: 0000-0002-6240-820X

Fomina D.S.

Sechenov First Moscow State Medical University (Sechenov University);
City Clinical Hospital No. 52

ORCID: 0000-0002-5083-6637

Ladygina E.A.

Sklifosovsky Research Institute for Emergency Care

Simarova I.B.

Moscow City Hospital No. 52;
Sklifosovsky Research Institute for Emergency Care

Filatova A.P.

Sklifosovsky Research Institute for Emergency Care

Mutovina Z.Yu.

Moscow City Hospital No. 52;
Central State Medical Academy

Kovalevskaya E.A.

Moscow City Hospital No. 52

Unmut S.S.

Center of Analytical Development of Social Sector

Maltseva N.P.

Moscow City Hospital No. 52

Vasin E.A.

Moscow City Hospital No. 52

Received:

04.07.2020

Accepted:

24.08.2020

List of references:

Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. European Journal of Clinical Microbiology and Infectious Diseases. 2005;24(1):44-46. https://doi.org/10.1007/s10096-004-1271-9
Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai KY, Koo CK, Buckley T, Chow FL, Wong KK, Chan HS, Ching CK, Tang BS, Lau CC, Li IW, Liu SH, Chan KH, Lin CK, Yuen KY. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clinical Infectious Diseases. 2011;52(4):447-456. https://doi.org/10.1093/cid/ciq106
Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM, Baker S, Nicol S, Conton B, Johnson W, Abiri OT, Kargbo O, Kamara P, Goba A, Russell JB, Gevao SM. Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. The Journal of Infection. 2017;74(3):302-309. https://doi.org/10.1016/j.jinf.2016.11.009
Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, Rojas-Villarraga A, Ramírez-Santana C, Díaz-Coronado JC, Manrique R, Mantilla RD, Shoenfeld Y, Anaya JM. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmunity Reviews. 2020;19(7):102554. https://doi.org/10.1016/j.autrev.2020.102554
Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, Carter RE, Klompas AM, Wiggins CC, Shepherd JR, Rea RF, Whelan ER, Clayburn AJ, Spiegel MR, Johnson PW, Lesser ER, Baker SE, Larson KF, Ripoll JG, Andersen KJ, Hodge DO, Kunze KL, Buras MR, Vogt MN, Herasevich V, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, Van Buskirk CM, Winters JL, Stubbs JR, Paneth NS, Verdun NC, Marks P, Casadevall A. Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients. The Journal of Clinical Investigation. 2020;130(9):4791-4797. https://doi.org/10.1172/JCI140200
Peng F, Tu L, Yang Y, Hu P, Wang R, Hu Q, Cao F, Jiang T, Sun J, Xu G, Chang C. Management and Treatment of COVID-19: The Chinese Experience. The Canadian Journal of Cardiology. 2020;36(6):915-930. https://doi.org/10.1016/j.cjca.2020.04.010
Thompson C, Grayson N, Paton R, Lourenco J, Penman BS, Lee L, Odon V, Mongkolsapaya J, Chinnakannan S, Dejnirattisai W, Edmans M, Fyfe A, Imlach C, Kooblall K, Lim N, Liu C, Lopez-Camacho C, McInally C, Ramamurthy N, Ratcliff J, Supasa P, Wang B, Mentzer A, Turner M, Semple MG, Baillie JK, ISARIC4C Investigators, Harvala H, Screaton GR, Temperton N, Klenerman P, Jarvis LM, Gupta S, Simmonds P. Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors — a pilot study of the value of serology to determine population exposure. Med Rxiv: the Preprint Server for Health Sciences. Preprint 2020. https://doi.org/10.1101/2020.04.13.20060467
Joyner MJ, Valk SJ, Piechotta V, Chai KL, Doree C, Monsef I, Wood EM, Lamikanra A, Kimber C, McQuilten Z, So-Osman C, Estcourt LJ, Skoetz N. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. The Cochrane Database of Systematic Reviews. 2020;5(5):CD013600. https://doi.org/10.1002/14651858:CD013600
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 Critically Ill Patients With COVID-19 with Convalescent Plasma. JAMA. 2020;323(16):1582-1589. https://doi.org/10.1001/jama.2020.4783
Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, Eubank T, Bernard DW, Eagar TN, Long SW, Subedi S, Olsen RJ, Leveque C, Schwartz MR, Dey M, Chavez-East C, Rogers J, Shehabeldin A, Joseph D, Williams G, Thomas K, Masud F, Talley C, Dlouhy KG, Lopez BV, Hampton C, Lavinder J, Gollihar JD, Maranhao AC, Ippolito GC, Saavedra MO, Cantu CC, Yerramilli P, Pruitt L, Musser JM. Treatment of COVID-19 Patients with Convalescent Plasma in Houston, Texas. MedRxiv: the Preprint Server for Health Sciences. Preprint 2020.05.08.20095471. https://doi.org/10.1101/2020.05.08.20095471
Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H, Hu C, Tao C, Yang R, Wang J, Yu Y, Guo Y, Wu X, Xu Z, Zeng L, Xiong N, Chen L, Wang J, Man N, Liu Y, Xu H, Deng E, Zhang X, Li C, Wang C, Su S, Zhang L, Wang J, Wu Y, Liu Z. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA: Journal of the American Medical Association. 2020;324(5):460-470. https://doi.org/10.1001/jama.2020.10044
Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, Ng MH, Chan P, Cheng G, Sung JJ. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clinical Microbiology and Infection. 2004;10(7):676-678. https://doi.org/10.1111/j.1469-0691.2004.00956.x
Lai ST. Treatment of severe acute respiratory syndrome. European Journal of Clinical Microbiology and Infectious Diseases. 2005;24(9):583-591. https://doi.org/10.1007/s10096-005-0004-z
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, Nguyen-Van-Tam JS, Beck CR; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. The Journal of Infectious Diseases. 2015;211(1):80-90. https://doi.org/10.1093/infdis/jiu396
Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, Wiggins CC, Senefeld JW, Klompas AM, Hodge DO, Shepherd JRA, Rea RF, Whelan ER, Clayburn AJ, Spiegel MR, Baker SE, Larson KF, Ripoll JG, Andersen KJ, Buras MR, Vogt MNP, Herasevich V, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, van Buskirk CM, Winters JL, Stubbs JR, van Helmond N, Butterfield BP, Sexton MA, Diaz Soto JC, Paneth NS, Verdun NC, Marks P, Casadevall A, Fairweather D, Carter RE, Wright RS. Safety update: COVID-19 convalescent plasma in 20 000 hospitalized patients. Mayo Clinic Proceedings. 2020;95(9):1888-1897. https://doi.org/10.1016/j.mayocp.2020.06.028
Chen B, Xia R. Early experience with convalescent plasma as immunotherapy for COVID-19 in China: Knowns and unknowns. Vox Sanguinis. 2020;10.1111/vox.12968. Advance online publication. https://doi.org/10.1111/vox.12968
Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, Chen Q, Zhang L, Zhong Q, Zhang X, Zou Y, Zhang S Treatment with Convalescent Plasma for Critically Ill Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Chest. 2020;158(1):9-13. https://doi.org/10.1016/j.chest.2020.03.039

Close metadata